On April 7, 2026, HexemBio announced its public launch as a biotechnology company developing the breakthrough blood stem cell rejuvenation therapy, alongside the close of a $10.4 million seed round. The round is led by Draper Associates with participation from SOSV, Seraphim, and other strategic investors. The funding will be used to finalize HexemBio’s IND-enabling studies and GMP manufacturing, with the company targeting first-in-human trials in 2027. Wilson Sonsini Goodrich & Rosati advised HexemBio on the transaction.

The Wilson Sonsini team that advised HexemBio on the transaction was led by Elton Satusky, Tori Fong, and Kathy Jordan.

For more information, see HexemBio’s news release. Additional coverage can be found on Axios.